Literature DB >> 26868393

Draft Genome Sequence of Proteus mirabilis NO-051/03, Representative of a Multidrug-Resistant Clone Spreading in Europe and Expressing the CMY-16 AmpC-Type β-Lactamase.

Marco Maria D'Andrea1, Tommaso Giani1, Lucia Henrici De Angelis1, Nagaia Ciacci2, Marek Gniadkowski3, Vivi Miriagou4, Francesca Torricelli5, Gian Maria Rossolini6.   

Abstract

Proteus mirabilis NO-051/03, representative of a multidrug-resistant clone expressing the CMY-16 AmpC-type β-lactamase and circulating in Europe since 2003, was sequenced by a MiSeq platform using a paired-end approach. The genome was assembled in 100 scaffolds with a total length of 4,197,318 bp. Analysis of the draft genome sequence revealed the presence of several acquired resistance determinants to β-lactams, aminoglycosides, phenicols, tetracyclines, trimethoprim, and sulfonamides, of one plasmid replicon, and of a type I-E clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein (Cas) adaptive immune system.
Copyright © 2016 D’Andrea et al.

Entities:  

Year:  2016        PMID: 26868393      PMCID: PMC4751317          DOI: 10.1128/genomeA.01702-15

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Proteus mirabilis is one of the leading causes of urinary tract infections, especially in patients with functional or structural abnormalities of the urinary tract or with indwelling catheters, but it can also cause infections of other sites and bacteremia (1). In this species, which lacks functional chromosomal β-lactamase genes, acquired β-lactamase genes play an important role in the evolution of antibiotic resistance (2). P. mirabilis NO-051/03 (also referred as IT NO-051/03) (3) was isolated in 2003 from a skin and soft tissue infection sample from a hospitalized patient from northern Italy (Novara) (4). The strain was resistant to penicillins and expanded-spectrum cephalosporins, due to the production of an acquired AmpC-type β-lactamase (ACBL) of the CMY lineage, named CMY-16 (3–5), and also to fluoroquinolones. The strain, which caused a clonal outbreak in northern Italy, was subsequently found to be highly related to a clone spreading in Europe and North Africa since the 1990s (3). Bacterial DNA was subjected to whole-genome sequencing with a MiSeq platform (Illumina, Inc., San Diego, CA), using a 2 × 250-bp paired-end approach. In total, 2,216,404 reads were obtained and assembled using ABySS (6) into 100 scaffolds (>208 bp in size), with a total length of 4,197,318 bp and an N50 of 160,469 bp. The genome raw coverage was ≈130×. The average G+C content was 39%. A total of 3,778 coding sequences (CDSs), 82 tRNAs, 48 rRNAs, and 2 clustered regularly interspaced short palindromic repeat (CRISPR) systems were annotated by PGAP (http://www.ncbi.nlm.nih.gov/genome/annotation_prok). Further analysis showed the presence of a type I-E CRISPR-associated protein (Cas) adaptive immune system characterized by 20 spacers, of which 16 lacked any detectable identity with sequences in nucleotide databases, while 3 matched prophage sequences, and one matched a DNA fragment present between the mucB and resD genes in several conjugative IncL/M-type plasmids. These data suggest the ability of NO-051/03 to resist invasion by a number of phages and IncL/M-type plasmids. The antimicrobial resistome of NO-051/03 was investigated with ResFinder (7), which confirmed the presence of two acquired β-lactamase genes (blaCMY-16 and blaTEM-1b) and detected additional acquired resistance genes to aminoglycosides (strAB, aacA4, aac(-I, aadA1, and aph(3′)-Ic), aminoglycosides and quinolones (aac(6′)Ib-cr), chloramphenicol (cat and catA1), tetracyclines (tet(A)), trimethoprim (dfrA1), and sulfonamides (sul1 and sul2). Further analysis of the quinolone resistance-determining regions of topoisomerase genes (8) showed the presence of mutations previously linked to reduced susceptibility to fluoroquinolones, namely, those encoding S83R in GyrA, S464Y in GyrB, and S80R in ParC. PlasmidFinder (9) detected the presence of an IncQ1 replicon, while PHAST (10) revealed the presence of 5 intact, 2 incomplete, and 2 putative prophages. To the best of our knowledge, this is the first genome sequencing project of a P. mirabilis isolate producing an ACBL. The results from this project are expected to broaden the knowledge on the genetic factors that have contributed to the successful international spread of such isolates.

Nucleotide sequence accession numbers.

The complete genome sequence of P. mirabilis NO-051/03 was deposited at DDBJ/EMBL/GenBank databases under the accession number LGAY00000000. The version described in this paper is the first version, LGAY01000000.
  10 in total

1.  CMY-16, a novel acquired AmpC-type beta-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy.

Authors:  Marco M D'Andrea; Elisabetta Nucleo; Francesco Luzzaro; Tommaso Giani; Roberta Migliavacca; Francesca Vailati; Vesselina Kroumova; Laura Pagani; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  ABySS: a parallel assembler for short read sequence data.

Authors:  Jared T Simpson; Kim Wong; Shaun D Jackman; Jacqueline E Schein; Steven J M Jones; Inanç Birol
Journal:  Genome Res       Date:  2009-02-27       Impact factor: 9.043

Review 3.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options.

Authors:  Ana L Flores-Mireles; Jennifer N Walker; Michael Caparon; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2015-04-08       Impact factor: 60.633

4.  Evolution and spread of a multidrug-resistant Proteus mirabilis clone with chromosomal AmpC-type cephalosporinases in Europe.

Authors:  M M D'Andrea; E Literacka; A Zioga; T Giani; A Baraniak; J Fiett; E Sadowy; P T Tassios; G M Rossolini; M Gniadkowski; V Miriagou
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

Review 5.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

6.  In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing.

Authors:  Alessandra Carattoli; Ea Zankari; Aurora García-Fernández; Mette Voldby Larsen; Ole Lund; Laura Villa; Frank Møller Aarestrup; Henrik Hasman
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

7.  DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis.

Authors:  L M Weigel; G J Anderson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.

Authors:  Francesco Luzzaro; Gioconda Brigante; Marco Maria D'Andrea; Beatrice Pini; Tommaso Giani; Elisabetta Mantengoli; Gian Maria Rossolini; Antonio Toniolo
Journal:  Int J Antimicrob Agents       Date:  2008-12-17       Impact factor: 5.283

9.  Identification of acquired antimicrobial resistance genes.

Authors:  Ea Zankari; Henrik Hasman; Salvatore Cosentino; Martin Vestergaard; Simon Rasmussen; Ole Lund; Frank M Aarestrup; Mette Voldby Larsen
Journal:  J Antimicrob Chemother       Date:  2012-07-10       Impact factor: 5.790

10.  PHAST: a fast phage search tool.

Authors:  You Zhou; Yongjie Liang; Karlene H Lynch; Jonathan J Dennis; David S Wishart
Journal:  Nucleic Acids Res       Date:  2011-06-14       Impact factor: 16.971

  10 in total
  1 in total

Review 1.  Proteus spp. as Putative Gastrointestinal Pathogens.

Authors:  Amy L Hamilton; Michael A Kamm; Siew C Ng; Mark Morrison
Journal:  Clin Microbiol Rev       Date:  2018-06-13       Impact factor: 26.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.